Maged Shenouda's Insider Trades & SAST Disclosures
Maged Shenouda's most recent trade in Relmada Therapeutics Inc was a trade of 90,000 Common Stock done at an average price of $0.5 . Disclosure was reported to the exchange on May 16, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Maged Shenouda.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.49 per share. | 16 May 2025 | 90,000 | 228,335 (1%) | 0% | 0.5 | 43,686 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.52 per share. | 16 May 2025 | 60,000 | 288,335 (1%) | 0% | 0.5 | 31,422 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.44 per share. | 16 May 2025 | 50,000 | 138,335 (0%) | 0% | 0.4 | 22,100 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.95 per share. | 09 Sep 2024 | 24,120 | 88,335 (0%) | 0% | 3.0 | 71,154 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.73 per share. | 09 Sep 2024 | 21,118 | 64,215 (0%) | 0% | 2.7 | 57,652 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.55 per share. | 09 Sep 2024 | 8,194 | 43,097 (0%) | 0% | 2.6 | 20,895 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 54,624 | 136,714 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 24 May 2024 | 54,624 | 82,090 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Shenouda Maged | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.89 per share. | 29 Jan 2024 | 15,000 | 28,028 (0%) | 0% | 3.9 | 58,323 | Common Stock |
| Relmada Therapeutics Inc | Shenouda Maged | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.65 per share. | 29 Jan 2024 | 10,800 | 13,028 (0%) | 0% | 3.7 | 39,450 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.06 per share. | 29 Jan 2024 | 6,875 | 34,903 (0%) | 0% | 4.1 | 27,943 | Common Stock |
| Relmada Therapeutics Inc | Shenouda Maged | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 82,090 | 82,090 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 317,643 | 512,560 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Other type of transaction at price $ 0.00 per share. | 16 Dec 2022 | 200,000 | 0 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 194,917 | 194,917 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 295,211 | 522,729 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 227,518 | 227,518 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 10,000 | 70,350 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 08 Mar 2021 | 10,000 | 12,228 (0%) | 0% | 3.2 | 32,400 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.42 per share. | 08 Mar 2021 | 5,727 | 6,401 (0%) | 0% | 35.4 | 202,857 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.11 per share. | 08 Mar 2021 | 2,373 | 2,228 (0%) | 0% | 35.1 | 83,313 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 36.02 per share. | 08 Mar 2021 | 1,800 | 4,601 (0%) | 0% | 36.0 | 64,836 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 08 Mar 2021 | 100 | 12,128 (0%) | 0% | 35 | 3,500 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2021 | 3,000 | 80,250 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 24 Feb 2021 | 3,000 | 5,228 (0%) | 0% | 3.2 | 9,720 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 33.74 per share. | 24 Feb 2021 | 1,600 | 3,628 (0%) | 0% | 33.7 | 53,985 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 34.67 per share. | 24 Feb 2021 | 1,400 | 2,228 (0%) | 0% | 34.7 | 48,544 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.39 per share. | 11 Feb 2021 | 1,428 | 2,228 (0%) | 0% | 35.4 | 50,542 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 1,428 | 83,250 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 11 Feb 2021 | 1,428 | 3,656 (0%) | 0% | 3.2 | 4,627 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 08 Feb 2021 | 11,372 | 13,600 (0%) | 0% | 3.2 | 36,845 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 11,372 | 84,678 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.24 per share. | 08 Feb 2021 | 5,359 | 4,638 (0%) | 0% | 35.2 | 188,843 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 08 Feb 2021 | 3,603 | 9,997 (0%) | 0% | 35.0 | 126,242 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.20 per share. | 08 Feb 2021 | 2,410 | 2,228 (0%) | 0% | 35.2 | 84,825 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 02 Feb 2021 | 3,200 | 5,428 (0%) | 0% | 3.2 | 10,368 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 3,200 | 96,050 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 02 Feb 2021 | 3,100 | 2,328 (0%) | 0% | 35.0 | 108,634 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 02 Feb 2021 | 100 | 2,228 (0%) | 0% | 35 | 3,500 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 3,000 | 99,250 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 27 Jan 2021 | 3,000 | 5,228 (0%) | 0% | 3.2 | 9,720 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 31.59 per share. | 27 Jan 2021 | 1,800 | 3,428 (0%) | 0% | 31.6 | 56,862 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 32.43 per share. | 27 Jan 2021 | 1,200 | 2,228 (0%) | 0% | 32.4 | 38,916 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 22 Jan 2021 | 4,000 | 6,228 (0%) | 0% | 3.2 | 12,960 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 4,000 | 102,250 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 324.00 per share. | 22 Jan 2021 | 4,000 | 6,228 (0%) | 0% | 324 | 1,296,000 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.41 per share. | 22 Jan 2021 | 1,704 | 4,524 (0%) | 0% | 35.4 | 60,339 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.27 per share. | 22 Jan 2021 | 1,280 | 2,835 (0%) | 0% | 35.3 | 45,146 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 35.16 per share. | 22 Jan 2021 | 607 | 2,228 (0%) | 0% | 35.2 | 21,342 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Sale of securities on an exchange or to another person at price $ 36.15 per share. | 22 Jan 2021 | 409 | 4,115 (0%) | 0% | 36.1 | 14,785 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 127,500 | 127,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 127,500 | 127,500 | - | - | Options to purchase common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges